 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
15 January 1998 | Volume 128 Issue 2 | Pages 127-137
Interleukin-6, an inflammatory cytokine, is characterized by pleiotropy and redundancy of action. Apart from its hematologic, immune, and hepatic effects, it has many endocrine and metabolic actions. Specifically, it is a potent stimulator of the hypothalamic-pituitary-adrenal axis and is under the tonic negative control of glucocorticoids. It acutely stimulates the secretion of growth hormone, inhibits thyroid-stimulating hormone secretion, and decreases serum lipid concentrations. Furthermore, it is secreted during stress and is positively controlled by catecholamines. Administration of interleukin-6 results in fever, anorexia, and fatigue. Elevated levels of circulating interleukin-6 have been seen in the steroid withdrawal syndrome and in the severe inflammatory, infectious, and traumatic states potentially associated with the inappropriate secretion of vasopressin. Levels of circulating interleukin-6 are also elevated in several inflammatory diseases, such as rheumatoid arthritis. Interleukin-6 is negatively controlled by estrogens and androgens, and it plays a central role in the pathogenesis of the osteoporosis seen in conditions characterized by increased bone resorption, such as sex-steroid deficiency and hyperparathyroidism. Overproduction of interleukin-6 may contribute to illness during aging and chronic stress. Finally, administration of recombinant human interleukin-6 may serve as a stimulation test for the integrity of the hypothalamic-pituitary-adrenal axis.
ARTICLE
The Pathophysiologic Roles of Interleukin-6 in Human Disease
Dr. Dimitris A. Papanicolaou (Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health [NIH], Bethesda, Maryland): During inflammation, the inflammatory cytokines tumor necrosis factor-
, interleukin-1, and interleukin-6 are secreted, in that order [1, 2]. Interleukin-6 then inhibits the secretion of tumor necrosis factor- and interleukin-1 [3], activates the production of acute-phase reactants from the liver [4], and stimulates the hypothalamic-pituitary-adrenal axis [5] to help control the inflammation. In this sense, interleukin-6 is both a proinflammatory and an anti-inflammatory cytokine. It is produced not only by immune and immune accessory cells (such as monocytes, macrophages, lymphocytes, endothelial cells, fibroblasts, mast cells, astrocytes, and µglia) but also by many nonimmune cells and organs (such as osteoblasts, bone marrow stromal cells, keratinocytes, synoviocytes, chondrocytes, intestinal epithelial cells, Leydig cells of the testis, folliculostellate cells of the pituitary, endometrial stromal cells, trophoblasts, and vascular smooth-muscle cells) [4, 6-12]. What makes interleukin-6 particularly interesting to physicians is its marked pleiotropy and its involvement not only in inflammation but in the regulation of endocrine and metabolic functions. Its diverse actions are summarized in the Table 1 [13].
|
Molecular Biology of Interleukin-6
|
|---|
B, which is a major mediator of inflammatory stimuli [15, 16] (Figure 1).
|
Interleukin-6 exerts its broad range of action through the interleukin-6 receptor, a single-pass transmembrane receptor not directly involved in signal transduction. Instead, activation of the receptor by interleukin-6 induces homodimerization of another transmembrane receptor, gp130, which initiates the transduction cascade [13].
The interleukin-6 receptor has a second soluble form that consists of the extracellular domain of the membrane receptor. Interleukin-6 also activates gp130 through this soluble form, even on cells that lack the interleukin-6 receptor on their membranes [17, 18]. For example, interleukin-6 can cause cardiac hypertrophy through gp130, even though cardiac myocytes lack the interleukin-6 receptor. The gp130 receptor is shared by many cytokines and growth factors for signal transduction, including interleukin-11, oncostatin-M, leukemia inhibitory factor, ciliary neurotrophic factor, cardiotropin-1, and leptin [13] (Figure 2).
|
Endocrine and Metabolic Actions of Interleukin-6
|
|---|
|
Hypothalamic-Pituitary-Adrenal Axis
Animal studies have shown that interleukin-6 acutely activates the hypothalamic-pituitary-adrenal axis by acting primarily on the corticotropin-releasing hormone neuron. Specifically, a blockade of corticotropin-releasing hormone inhibits the effects of exogenous interleukin-6 on the hypothalamic-pituitary-adrenal axis in rats [19]. Subcutaneous administration of interleukin-6 to normal human volunteers resulted in elevated plasma levels of adrenocorticotropin hormone (ACTH) and then an increase in plasma levels of cortisol [20]. The plasma level of cortisol peaked after the plasma level of ACTH peaked; this indicates that, at least in this acute setting, cortisol's response to interleukin-6 administration is mediated by release of ACTH [21].
Interleukin-6 seems to be one of the most potent stimuli of the hypothalamic-pituitary-adrenal axis in humans. Subcutaneous administration of interleukin-6 once a day for 7 days resulted in remarkable enlargement of the adrenal glands similar to that seen after prolonged activation of the adrenal glands by ACTH (as in Cushing disease or ectopic ACTH production) [22].
In animals and humans, glucocorticoids inhibit production of interleukin-6 in vitro and in vivo [23, 24]. In a recent study [25], administration of hydrocortisone or dexamethasone attenuated exercise-induced elevation of plasma levels of interleukin-6. Conversely, correction of hypercortisolism by surgical removal of a corticotroph adenoma when plasma levels of cortisol were undetectable increased plasma levels of interleukin-6 more than fourfold in patients with Cushing disease [26]. Therefore, interleukin-6 stimulates the hypothalamic-pituitary-adrenal axis and cortisol exerts negative feedback on secretion of interleukin-6. Interleukin-6 thus functions as a hormone in the traditional sense: It participates in a feedback loop of the hypothalamic-pituitary-adrenal axis.
Thermogenesis and Basal Metabolic Rate
Several cytokines, especially interleukin-1, are pyrogenic in humans and animals [27]. Administration of interleukin-6 causes elevations in body temperature and resting metabolic rate in humans [20]. In animals, the fact that nonsteroidal anti-inflammatory agents can inhibit the thermogenic effect of interleukin-6 suggests that this effect may be mediated by prostanoids [28].
The Steroid Withdrawal Syndrome
The concept of the steroid withdrawal syndrome was introduced in 1965 by Amatruda and colleagues [29]. The syndrome is characterized by fever; headache; nausea; fatigue; malaise; somnolence; anorexia; and, less commonly, flu-like symptoms, such as arthralgias and myalgias. These symptoms occur during an abrupt reduction in levels of circulating cortisol and have been seen in patients who became severely hypocortisolemic when they underwent curative transsphenoidal surgery for Cushing disease. At that time, plasma levels of interleukin-6 were greatly elevated [26]. Normal volunteers and patients who received interleukin-6 had similar symptoms; this suggests that interleukin-6 participates in the pathogenesis of the steroid withdrawal syndrome [20, 21, 30].
Vasopressin and the Syndrome of Inappropriate Secretion of Antidiuretic Hormone
The release of arginine vasopressin by the posterior pituitary is controlled by changes in intravascular volume and by osmotic stimuli. The syndrome of the inappropriate secretion of antidiuretic hormone occurs in the absence of serum hyperosmolarity or hypovolemia and can be caused by several conditions, including certain types of trauma, infections (meningitis and pneumonia), and inflammation [31]. During the syndrome, production of inflammatory cytokines (including interleukin-6) increases. Because high doses of interleukin-6 increase plasma levels of vasopressin in humans [32], endogenous interleukin-6 may also participate in the pathogenesis of this syndrome.
Interleukin-6 as a Stress Hormone
Because it innervates many immune organs, such as the spleen and the thymus, the autonomic nervous system interacts directly with the immune system [33, 34]. Stress or administration of adrenaline to animals elevates levels of endogenous interleukin-6, but pretreatment with a ß-adrenergic antagonist abolishes this effect. These effects suggest that interleukin-6 secretion is stimulated through ß-adrenergic receptors [35, 36]. In a recent study [37], administering adrenaline to humans increased plasma levels of interleukin-6. In normal volunteers, treadmill exercise also increased levels of plasma interleukin-6. In addition, peak plasma levels of catecholamines were positively correlated with plasma levels of interleukin-6 [25]. These data indicate that interleukin-6 is secreted during stress, probably through a ß-adrenergic receptor mechanism, and that it participates in the stress response.
Lipid Metabolism
Normal volunteers had precipitous reductions in serum total cholesterol levels, apolipoprotein B levels (this reflects low-density lipoprotein cholesterol), and triglyceride levels within 24 hours of interleukin-6 administration [38]. During sustained elevation of plasma catecholamine levels (such as that which occurs immediately after myocardial infarction), serum lipid levels are temporarily reduced, rendering serum cholesterol measurements misleading [39]. Whether catecholamine-stimulated endogenous interleukin-6 contributes to the transient decrease in serum lipid concentrations observed in conditions with increased sympathoneural discharge requires further study.
Thyroid Axis and the Euthyroid Sick Syndrome
Exogenous interleukin-6 decreased the secretion of thyroid-stimulating hormone in animals in vivo [5], and interleukin-6 was recently shown to be associated with a decrease in serum levels of thyroid-stimulating hormone and triiodothyronine in humans within 4 hours of administration. Interleukin-6 seemed to have a more lasting effect on triiodothyronine levels; the decrease persisted for at least 24 hours after a single injection of interleukin-6 [20, 21]. Thus, interleukin-6 was associated with changes in thyroid function test results similar to those seen in the euthyroid sick syndrome, a condition of physiologic hypothyroidism that occurs during nonthyroidal illness, apparently in an attempt by the organism to conserve energy. Depending on the severity and duration of the illness, it ranges from an isolated decrease in serum triiodothyronine levels in mild cases to a decrease in serum levels of free thyroxine and, finally, to subnormal thyroid-stimulating hormone levels in more severe cases [40]. Interleukin-6 levels are frequently elevated in conditions that are associated with the euthyroid sick syndrome (such as infection or inflammation, major trauma or surgery, and prolonged stays in the intensive care unit) and are negatively correlated with serum triiodothyronine levels in nonthyroidal illness [41].
In summary, interleukin-6 seems to activate the hypothalamic-pituitary-adrenal axis, to be negatively controlled by glucocorticoids, to stimulate thermogenesis and the basal metabolic rate, and to participate in the pathogenesis of the steroid withdrawal syndrome. It also stimulates vasopressin secretion and is probably involved in the syndrome of inappropriate secretion of antidiuretic hormone. Furthermore, it participates in the stress response, probably downstream from the catecholamines, and acutely decreases serum lipid levels. Finally, it is associated with the suppression of thyroid function and is probably associated with the euthyroid sick syndrome.
Interleukin-6 in Autoimmune and Inflammatory Diseases
|
|---|
Interleukin-6 in Transgenic and Gene Knockout Mice
One of the most incisive approaches to elucidating the role of interleukin-6 in inflammation and immunity uses genetically engineered transgenic [42-45] and gene knockout mice [46-52]. Overexpression of interleukin-6 in transgenic mice results in massive plasmacytosis in the spleen, lymph nodes, thymus, lung, liver, and kidney that is associated with pronounced hypergammaglobulinemia, particularly of the IgG-1 subclass. In the context of these relatively specific B-lymphocyte growth and differentiation effects, it should be noted that interleukin-6 receptors are expressed on activated but not resting B cells.
In addition to showing plasma cell expansion, interleukin-6 transgenic mice exhibit thrombocytosis and marked increases in the number of mature megakaryocytes in the bone marrow. These mice also have kidney abnormalities, particularly mesangial proliferative glomerulonephritis. The murine syndrome that results from persistent overexpression of interleukin-6 resembles a human condition known as the Castleman syndrome [53], which is associated with lymph node enlargement, massive hypergammaglobulinemia, and increased synthesis of acute-phase protein. In some cases, the condition progresses to myeloma.
The converse of overexpression of murine transgenic interleukin-6 is represented by murine interleukin-6 gene knockout mice. In response to diverse stimuli, mice with no interleukin-6 gene manifest a major impairment in acute-phase protein synthesis. They also have reduced antimicrobial resistance, impaired T-cell growth and function, impaired B-cell maturation, and deficient mucosal IgA production. The numbers of uncommitted progenitor cells in the bone marrow are reduced, and the capacity to generate leukocytosis is impaired.
Corticosteroid production in response to inflammatory stimuli in knockout mice has been reported as normal and subnormal [46, 47]. Production of tumor necrosis factor- is markedly increased in these mice compared with normal mice, and corticosteroids provide feedback suppression on production of tumor necrosis factor-. These observations suggest that restraints on the production of proinflammatory mediators by the hypothalamic-pituitary-adrenal axis are blunted in interleukin-6 knockout mice.
The acute-phase response consists of enhanced production of more than 40 proteins [54] that have either proinflammatory or anti-inflammatory properties, depending on the nature of the stimulus. The acute-phase proteins include several components of the complement system, which are involved in the accumulation of phagocytes at an inflammatory site and the killing of microbial pathogens. C-reactive protein, a prominent acute-phase protein, binds various pathogens and materials from damaged cells, promotes opsonization of these materials, and activates the complement system. In this context, interleukin-6-induced production of acute-phase proteins can be viewed as a protective host defense mechanism that limits tissue injury [55, 56].
The concept of increased production of acute-phase protein as a host defense mechanism becomes more complicated when discussed in terms of the response of interleukin-6 gene-deficient mice to various defined stimuli [47, 49, 50]. Synthesis of acute-phase protein in interleukin-6 knockout mice is greatly impaired in response to nonspecific irritants. Thus, interleukin-6-deficient mice injected intraperitoneally with a sterile irritant, such as turpentine, show only mild anorexia, do not lose weight, and have markedly blunted synthesis of acute-phase protein. In contrast, wild-type mice stop eating, lose weight, and have markedly elevated levels of acute-phase protein. Moreover, normal mice show increases in plasma levels of tumor necrosis factor- and interleukin-6, whereas the plasma levels of either cytokine do not increase in interleukin-6-deficient mice. No increase in mortality rate is associated with the response to turpentine in either the knockout or the wild-type mice. Therefore, in the context of the response to a sterile irritant, the interleukin-6-dependent acute-phase response is associated with greater illness and tissue injury compared with the absence of interleukin-6 production [46, 47].
However, interleukin-6-deficient mice do not develop leukocytosis in response to an infectious agent, such as Listeria monocytogenes, whereas production of interferon-
, which is critical in many host defense mechanisms, is similar to that found in wild-type mice. The mortality rate among interleukin-6 knockout mice infected with L. monocytogenes is markedly increased compared with that among normal mice, indicating that interleukin-6 is critical to host defense and survival in response to this infectious agent [49, 50, 52].
Rheumatoid Arthritis
Many clinical symptoms and signs associated with rheumatoid arthritis have been linked to interleukin-6 [57-64]. For example, severe disease is typically characterized by thrombocytosis, hypergammaglobulinemia, an elevated erythrocyte sedimentation rate, and elevated levels of C-reactive protein; these abnormalities are highly correlated with plasma and synovial levels of interleukin-6. In fact, persistently elevated levels of C-reactive protein predict a very poor outcome for patients with rheumatoid arthritis [59]. In addition, systemic and periarticular bone loss, which is common in severe disease, is highly correlated with interleukin-6 levels in bone marrow [57, 62]. Consistent with these data, small-scale therapeutic studies with humanized anti-interleukin-6 antibodies have noted improvement in clinical and laboratory variables [61].
An interesting association between interleukin-6 and rheumatoid arthritis relates to age at onset and sex-steroid hormone deficiency. Rheumatoid arthritis is much more common in women than in men, and the peak incidence of disease occurs in the perimenopausal, postmenopausal, or postpartum period: that is, when levels of gonadal steroid hormones are low. All available data indicate that interleukin-6 production is inversely correlated with gonadal steroid levels [48, 51, 65] and that interleukin-6 production increases with age. Rheumatoid arthritis is uncommon in men younger than 45 years of age, but the incidence increases markedly in older men and approaches the incidence in women. Because androgen levels decrease with aging, androgens may be involved in regulating increased susceptibility to disease expression [65, 66].
Links between the hypothalamic-pituitary-adrenal axis and interleukin-6 in rheumatoid arthritis are of great interest. Interleukin-6 is produced at high levels and in a circadian fashion in patients with rheumatoid arthritis, with peak levels occurring between 4 a.m. and 6 a.m. Patients with rheumatoid arthritis have "inappropriately normal" or, less commonly, subnormal (albeit circadian) daily cortisol production. This suggests a mismatch in sensitivity between interleukin-6 and the hypothalamic-pituitary-adrenal axis in rheumatoid arthritis [67, 68].
Systemic Lupus Erythematosus
The role of interleukin-6 in systemic lupus erythematosus is still unclear [69-72]. Whereas elevated plasma levels of interleukin-6 are a common feature of active disease, levels of circulating interleukin-6 are normal in the inactive form. It is interesting that levels of C-reactive protein (a surrogate for interleukin-6 action) but not erythrocyte sedimentation rates are usually normal in patients with lupus. This raises the question of whether patients with lupus may have a defect in selected components of the acute-phase response to interleukin-6 [64].
In summary, interleukin-6 seems to be a major mediator of the host response to tissue injury in many autoimmune and inflammatory diseases and plays an important role in regulating the immune, hepatic, hematopoietic, skeletal, and neuroendocrine systems. Abnormalities that lead to persistent oversecretion or undersecretion of interleukin-6 or excessive or blunted effects of interleukin-6 may be involved in various disease states, including autoimmune and inflammatory diseases.
Pathophysiologic Role of Interleukin-6 in Osteoporosis and Other Bone Diseases
|
|---|
Extensive evidence produced in the past few years indicates that the cellular activity of bone marrow and bone remodeling are tightly linked. Indeed, it is now thought that bone homeostasis, like homeostasis of other regenerating tissues, depends on the orderly replenishment of cellular constituents and that the fundamental problem in osteoporosis is aberrant cell production relative to demand. Thus, an oversupply of osteoclasts relative to the need for remodeling (probably associated with a decreased rate of apoptosis) and an undersupply of osteoblasts relative to the need for cavity repair are the critical pathophysiologic changes in postmenopausal and age-related osteopenia, respectively [73].
Cytokines and Bone Remodeling
By stimulating the development of osteoclasts, interleukin-6 type cytokines play a profound role in skeletal homeostasis, and increasing evidence suggests that interleukin-6 type cytokines also promote the development of osteoblasts [74]. Moreover, it is now established that bone-active systemic hormones, such as sex steroids, parathyroid hormone, parathyroid hormone-related peptide, 1,25-dihydroxyvitamin D3, and thyroxine, exert their potent influences on bone remodeling and skeletal homeostasis by regulating the production and action of interleukin-6 and interleukin-11. Hormones affect the actions of these interleukins by regulating the expression of the receptors for these cytokines.
Role of Interleukin-6 and Its Receptors in the Osteoporosis of Sex-Steroid Deficiency
The production of interleukin-6 by cells of the stromal-osteoblastic lineage is inhibited in vitro by estrogen and androgen [51, 75] through receptor-mediated actions on the transcriptional activity of the interleukin-6 gene promoter [51, 76-78]. Conversely, estrogen loss results in increased production of interleukin-6 by ex vivo bone marrow cell cultures, and increased production of interleukin-6 follows the withdrawal of estradiol from primary cultures of calvarial cells [79]. In agreement with in vitro evidence, circulating levels of interleukin-6 are elevated in estrogen-deficient mice, rats, and humans [74]. Direct support for the contention that interleukin-6 is responsible for increased bone resorption after loss of sex steroids is derived from studies showing that injections of an interleukin-6-neutralizing antibody in female or male mice that have had gonadectomy prevents the increase in osteoclastogenesis in bone marrow and the increase in the number of osteoclasts in sections of trabecular bone [51, 80]. Furthermore, unlike wild-type controls, interleukin-6 knockout mice do not show cellular changes in the marrow and trabecular bone sections and are protected from the loss of trabecular bone after the loss of sex steroids [48, 51].
Even though interleukin-6 is implicated as a pathogenetic factor in osteoporosis, it does not seem to be important for osteoclastogenesis under normal conditions [51, 80, 81]. Thus, administering an interleukin-6-neutralizing antibody to estrogen-sufficient mice or ex vivo cultures of bone marrow cells from sex-steroid-sufficient mice has no effect on osteoclastogenesis. Furthermore, osteoclastogenesis is unaffected in interleukin-6-deficient mice [48, 51, 80], indicating that the osteoclastogenic process in the estrogen-sufficient state is insensitive to interleukin-6.
An explanation of the importance of interleukin-6 for bone remodeling in the sex-steroid-deficient state has been provided from evidence that sex steroids suppress not only the expression of interleukin-6 but also its receptor. Indeed, in vitro studies have determined that 17ß-estradiol or dihydrotestosterone decreased the amount of messenger RNA of the interleukin-6 receptor and messenger RNA of gp130 in cells of the bone marrow stromal-osteoblastic lineage. These agents also decreased levels of gp130 protein. Consistent with these findings, ovariectomy in mice increased the expression of interleukin-6 receptor and gp130 and the amount of interleukin-6 messenger RNA in ex vivo bone marrow cell cultures. These results were determined by quantitative reverse transcriptase polymerase chain reaction and confirmed on an individual cell basis by using in situ reverse transcriptase polymerase chain reaction [82].
Results of clinical studies indicate that the interleukin-6 receptor is upregulated after the loss of estrogen in humans. Girasole and coworkers [83] studied women who had hysterectomy alone, ovariectomy, or ovariectomy with transdermal estrogen replacement. In the course of 12 months, the expected increases in markers of bone formation and bone resorption were accompanied at the same time points by a 35% increase in levels of soluble interleukin-6 receptor and a 20% increase in serum levels of interleukin-6. Estrogen replacement reversed the increased levels of serum and soluble interleukin-6 receptor induced by ovariectomy. Similarly, Chen and colleagues [84] investigated 151 healthy women whose menstruation status differed and found that levels of soluble interleukin-6 receptor were substantially increased in postmenopausal women compared with premenopausal and perimenopausal women.
Role of Interleukin-6 in Other Disease States Characterized by Increased Bone Resorption
Evidence accumulated in the past 5 years to support the contention that interleukin-6 is a pathogenetic factor in osteoporosis that results from the loss of either male or female sex steroids has implicated interleukin-6 in the pathophysiology of several other diseases caused by increased osteoclastic bone resorption. These diseases include hyperparathyroidism [85, 86], Paget disease [87], multiple myeloma [88], rheumatoid arthritis [57, 89], Gorham-Stout disease [90], hyperthyroidism [91, 92], the McCune-Albright syndrome [93], and renal osteodystrophy [94]. An increase in the expression of the soluble interleukin-6 receptor has been shown in these diseases and in sex-steroid deficiency. The mechanism of increased production of interleukin-6 in these diseases is still unclear, with the exceptions of hyperparathyroidism (in which parathyroid hormone stimulates production of interleukin-6) and the McCune-Albright syndrome (in which the constitutive activation of the Gs-subunit of the G protein and the eventual increase in levels of intracellular cyclic adenosine 5'-monophosphate lead to elevated levels of interleukin-6 levels in the affected bone).
In conclusion, the increased rate of remodeling and bone loss that characterizes several disease states may be explained by increased osteoclast development caused by increased production or action of such cytokines as interleukin-6.
Integration of the Immune and Endocrine Systems by Interleukin-6
|
|---|
Interleukin-6 has a profound stimulatory effect on the stress system [20-22] and is secreted when the system is activated during inflammatory [98, 99] and (to a lesser extent) noninflammatory stress [25, 35, 36, 100]. Interleukin-6 may play a pathogenetic role in conditions related to chronic stress and physiologic aging. Aging is characterized by progressively increasing concentrations of glucocorticoids and catecholamines and decreasing production of growth and sex hormones, a pattern reminiscent of that seen in chronic stress (Figure 4). Recent studies [101, 102] have shown that plasma levels of interleukin-6 increase with age, probably as the result of catecholamine hypersecretion and sex-steroid hyposecretion, and that interleukin-6 levels correlate with the functional disability of elderly persons [103]. Therefore, interleukin-6 may contribute to the increased morbidity and mortality seen in chronically stressed or physiologically aging persons. The potential involvement of interleukin-6 in the pathophysiology of aging and chronic stress calls for research on ways to suppress its secretion or effects.
|
The presence of high levels of interleukin-6 in states characterized by fatigue or somnolence, such as glucocorticoid deficiency [26], rheumatoid arthritis [59, 63], and disorders of excessive daytime sleepiness [104]; the marked correlation of interleukin-6 with exercise-induced exhaustion (Papanicolaou DA, Singh A, Gold PW, Deuster PA, Chrousos GP. Exercise-induced fatigue correlates with plasma interleukin-6 [IL-6] levels in normal women. Presented at the Third International Congress of the International Society for Neuroimmunomodulation, 15 November 1996, Washington, DC); and the ability of interleukin-6 to cause fatigue [20, 21] suggest that it may be a fatigue-mediating factor whose suppression or neutralization may help alleviate these symptoms when necessary. Humanized neutralizing anti-interleukin-6 antibodies or interleukin-6 receptor antagonists may be particularly helpful in rehabilitating patients with rheumatic diseases and debilitating fatigue [61].
A recent study [105] provided indirect evidence that interleukin-6 may be involved in the pathogenesis of myocardial infarction. Specifically, men who had elevated baseline levels of C-reactive protein, a surrogate for interleukin-6 action [106], were at greater risk for myocardial infarction than men who had normal levels of C-reactive protein. In addition, marked gliosis occurs in the brains of transgenic animals in which interleukin-6 is overexpressed in the central nervous system [45]; this indicates that this cytokine may participate in the neurodegeneration and gliosis seen in such conditions as AIDS encephalopathy [107, 108] and Alzheimer disease [109, 110]. Thus, potential suppressants of interleukin-6 secretion or interleukin-6 antagonists might be a promising adjuvant therapy for such states.
The ability of interleukin-6 to stimulate secretion of corticotropin-releasing hormone in a dose-dependent manner suggests that this cytokine could be used for the differential diagnosis of disorders associated with abnormalities of the corticotropin-releasing hormone neuron. Thus, an interleukin-6 stimulation test could be useful in differentiating between the Cushing syndrome and pseudo-Cushing syndrome states (such as the combination of obesity and melancholic depression or chronic active alcoholism and the alcohol withdrawal syndrome) and between atypical and melancholic depression. Such a differentiation would be based on the fact that the corticotropin-releasing hormone neuron is chronically suppressed in the Cushing syndrome and chronically activated in pseudo-Cushing syndrome states [111]. In addition, melancholic depression and atypical depression are on opposite sides of the spectrum in terms of activity of the corticotropin-releasing hormone neuron [112-115].
Glossary
|
|---|
 Top Glossary Author & Article InfoReferences |
|---|
C/EBP: A transcription factor that regulates several adipocyte-specific and hepatocyte-specific genes.
C/EBPbeta (NF-IL6): A transcription factor that is minimally expressed in normal tissues but is drastically induced by stimulation of lipopolysaccharides, interleukin-1, tumor necrosis factor-, or interleukin-6.
c-fos: A transcription factor that regulates growth as a heterodimer with c-jun; the heterodimers bind to the AP-1 sites.
c-jun: A transcription factor that regulates growth as a heterodimer with c-fos; the heterodimers bind to the AP-1 sites.
Exon: A coding section of a gene retained at its messenger RNA before translation.
Intron: A noncoding section of a gene that is removed from RNA transcripts before they are translated.
NF-B: A transcription factor activated during inflammation.
Stress: Disturbance of homeostasis.
Th1: CD4+ cells that produce interleukin-2 and interferon-, which promote cellular immunity.
Th2: CD4+ cells that produce interleukin-4, which promotes humoral immunity. The term has been expanded to include cytokines that promote humoral immunity, such as interleukin-5, interleukin-9, interleukin-11, and interleukin-13.
Transcription: The making of an RNA molecule by using the information encoded in the DNA.
Transcription factor: A protein that binds to the regulatory regions of genes and influences their rates of transcription.
Dr. Wilder: Arthritis and Rheumatism Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Building 10, Room 9N240, 10 Center Drive MSC 1862, Bethesda, MD 20892.
Dr. Manolagas: Division of Endocrinology Metabolism and Center for Osteoporosis and Metabolic Bone Diseases, Department of Internal Medicine, University of Arkansas for Medical Sciences, 4301 West Markham Street, Slot 587, Little Rock, AR 72205-7199.
Dr. Chrousos: Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Building 10, Room 10N244, 10 Center Drive MSC 1862, Bethesda, MD 20892-1862.
Author and Article Information
|
|---|
|
TopGlossaryAuthor & Article InfoReferences |
|---|
References
|
|---|
|
TopGlossaryAuthor & Article InfoReferences |
|---|
1. van Deventer SJ, Buller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood. 1990; 76:2520-6.
2. Hesse DG, Tracey KJ, Fong Y, Manogue KR, Palladino MA Jr, Cerami A, et al. Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet. 1988; 166:147-53.
3. Schindler R, Mancilla J, Endres S, Ghorbani R, Clark SC, Dinarello CA. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood. 1990; 75:40-7.
4. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J. 1990; 265:621-36.
5. Lyson K, McCann SM. The effect of interleukin-6 on pituitary hormone release in vivo and in vitro. Neuroendocrinology. 1991; 54:262-6.
6. Vankelecom H, Carmeliet P, Van Damme J, Billiau A, Denef C. Production of interleukin-6 by folliculo-stellate cells of the anterior pituitary gland in a histiotypic cell aggregate culture system. Neuroendocrinology. 1989; 49:102-6.
7. Boockfor FR, Wang D, Lin T, Nagpal ML, Spangelo BL. Interleukin-6 secretion from rat Leydig cells in culture. Endocrinology. 1994; 134:2150-5.
8. McGee DW, Beagley KW, Aicher WK, McGhee JR. Transforming growth factor-ß and IL-1 ß act in synergy to enhance IL-6 secretion by the intestinal epithelial cell line, IEC-6. J Immunol. 1993; 151:970-8.
9. Kameda T, Matsuzaki N, Sawai K, Okada T, Saji F, Matsuda T, et al. Production of interleukin-6 by normal human trophoblast. Placenta. 1990; 11:205-13.
10. Loppnow H, Libby P. Proliferating or interleukin 1-activated human vascular smooth muscle cells secrete copious interleukin 6. J Clin Invest. 1990; 85:731-8.
11. Yang YC, Tsai S, Wong GG, Clark SC. Interleukin-1 regulation of hematopoietic growth factor production by human stromal fibroblasts. J Cell Physiol. 1988; 134:292-6.
12. Bellido T, Stahl N, Farruggella TJ, Borba V, Yancopoulos GD, Manolagas SC. Detection of receptors for interleukin-6, interleukin-11, leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor in bone marrow stromal/osteoblastic cells. J Clin Invest. 1996; 97:431-7.
13. Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp 130. Blood. 1995; 86:1243-54.
14. Sehgal PB. Regulation of IL6 gene expression. Res Immunol. 1992; 143:724-34.
15. Matsusaka T, Fujikawa K, Nishio Y, Mukaida N, Matsushima K, Kishimoto T, et al. Transcription factors NF-IL6 and NF-B synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc Natl Acad Sci U S A. 1993; 90:10193-7.
16. Akira S, Isshiki H, Nakajima T, Kinoshita S, Nishio Y, Hashimoto S, et al. A nuclear factor for the IL-6 gene (NF-IL6). Chem Immunol. 1992; 51:299-322.
17. Kishimoto T, Taga T, Akira S. Cytokine signal transduction. Cell. 1994; 76:253-62.
18. Stahl N, Yancopoulos GD. The alphas, betas, and kinases of cytokine receptor complexes. Cell. 1993; 74:587-90.
19. Naitoh Y, Fukata J, Tominaga T, Nakai Y, Tamai S, Mori K, et al. Interleukin-6 stimulates the secretion of adrenocorticotropic hormone in conscious, freely-moving rats. Biochem Biophys Res Commun. 1988; 155:1459-63.
20. Tsigos C, Papanicolaou DA, Defensor R, Mitsiadis CS, Kyrou I, Chrousos GP. Dose-effects of recombinant human interleukin-6 on pituitary hormone secretion and energy expenditure. Neuroendocrinology. 1997; 66:54-62.
21. Papanicolaou DA, Tsigos C, Torpy DJ, Defensor R, Thompson B, Chrousos GP. Recombinant interleukin-6 effects on pituitary secretion in humans [Abstract]. J Invest Med. 1996; 44:A266.
22. Mastorakos G, Chrousos GP, Weber JS. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab. 1993; 77:1690-4.
23. Breuninger LM, Dempsey WL, UhI J, Murasko DM. Hydrocortisone regulation of interleukin-6 protein production by a purified population of human peripheral blood monocytes. Clin Immunol Immunopathol. 1993; 69:205-14.
24. Rock CS, Coyle SM, Keogh CV, Lazarus DD, Hawes AS, Leskiw M, et al. Influence of hypercortisolemia on the acute-phase protein response to endotoxin in humans. Surgery. 1992; 112:467-74.
25. Papanicolaou DA, Petrides JS, Tsigos C, Bina S, Kalogeras KT, Wilder R, et al. Exercise stimulates interleukin-6 secretion: inhibition by glucocorticoids and correlation with catecholamines. Am J Physiol. 1996; 271(3 Pt 1):E601-5.
26. Papanicolaou DA, Tsigos C, Oldfield EH, Chrousos GP. Acute glucocorticoid deficiency is associated with plasma elevations of interleukin-6: does the latter participate in the symptomatology of the steroid withdrawal syndrome and adrenal insufficiency? J Clin Endocrinol Metab. 1996; 81:2303-6.
27. Rothwell NJ. Cytokines and thermogenesis. Int J Obes Relat Metab Disord. 1993; 17(Suppl 3):S98-S101, S115.
28. Rothwell NJ. CNS regulation of thermogenesis. Crit Rev Neurobiol. 1994; 8:1-10.
29. Amatruda TT Jr, Hurst MM, D'Esopo ND. Certain endocrine and metabolic facets of the steroid withdrawal syndrome. J Clin Endocrinol Metab. 1965; 25:1207-17.[Medline]
30. Papanicolaou DA. Cytokines and adrenal insufficiency. Curr Opin Endocrinol Metab. 1997; 4:194-8.
31. Baylis PH, Thompson CJ. Syndrome of inappropriate antidiuresis. In: Becker KL, Bilezikian JP, Bremner WJ, et al, eds. Principles and Practice of Endocrinology and Metabolism. Philadelphia: Lippincott; 1990:241-7.
32. Mastorakos G, Weber JS, Magiakou MA, Gunn H, Chrousos GP. Hypothalamic-pituitary-adrenal axis activation and stimulation of systemic vasopressin secretion by recombinant interleukin-6 in humans: potential implications for the syndrome of inappropriate vasopressin secretion. J Clin Endocrinol Metab. 1994; 79:934-9.
33. Felten DL, Felten SY, Carlson SL, Olschowka JA, Livnat S. Noradrenergic and peptidergic innervation of lymphoid tissue. J Immunol. 1985; 135:755s-65s.
34. Vizi ES, Orso E, Osipenko ON, Hasko G, Elenkov IJ. Neurochemical, electrophysiological and immunocytochemical evidence for a noradrenergic link between the sympathetic nervous system and thymocytes. Neuroscience. 1995; 68:1263-76.
35. van Gool J, van Vugt H, Helle M, Aarden LA. The relation among stress, adrenalin, interleukin 6 and acute phase proteins in the rat. Clin Immunol Immunopathol. 1990; 57:200-10.
36. Soszynski D, Kozak W, Conn CA, Rudolph K, Kluger MJ. Beta-adrenoceptor antagonists suppress elevation in body temperature and increase in plasma IL-6 in rats exposed to open field. Neuroendocrinology. 1996; 63:459-67.
37. Pelton GH, Price LH, Heninger GR. Epinephrine stimulates increased IL-6 blood levels in major depression [Abstract]. Proceedings of the Annual Meeting of the American College of Neuropsychopharmacology. 1995; 122.
38. Papanicolaou DA, Tsigos C, Torpy DJ, Defensor R, Thompson B, Chrousos GP. Serial fasting lipid profile changes after a single injection of interleukin-6 in normal volunteers [Abstract]. 10th International Congress of Endocrinology (ICE '96), 12-15 June 1996, San Francisco, USA. Bethesda, MD: Endocrine Soc Pr; 1996:346.
39. Brugada R, Wenger NK, Jacobson TA, Clark WS, Cotsonis G, Iglesias A. Changes in plasma cholesterol levels after hospitalization for acute coronary events. Cardiology. 1996; 87:194-9.
40. Wartofsky L, Burman KD. Alterations in thyroid function in patients with systemic illness: the "euthyroid sick syndrome." Endocr Rev. 1982; 3:164-217.
41. Boelen A, Platvoet-Ter Schiphorst MC, Wiersinga WM. Association between serum interleukin-6 and serum 3,5,3-triiodothyronine in nonthyroidal illness. J Clin Endocrinol Metab. 1993; 77:1695-9.
42. Suematsu S, Matsuda T, Aozasa K, Akira S, Nakano N, Ohno S, et al. IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci U S A. 1989; 86:7547-51.
43. Woodroofe C, Muller W, Ruther U. Long-term consequences of interleukin-6 overexpression in transgenic mice. DNA Cell Biol. 1992; 11:587-92.
44. Peters M, Jacobs S, Ehlers M, Vollmer P, Mullberg J, Wolf E, et al. The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med. 1996; 183:1399-406.
45. Cambell IL, Abraham CR, Masliah E, Kemper P, Inglis JD, Oldstone MB, et al. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc Natl Acad Sci U S A. 1993; 90:10061-5.
46. Libert C, Takahashi N, Cauwels A, Brouckaert P, Bluethmann H, Fiers W. Response of interleukin-6-deficient mice to tumor necrosis factor-induced metabolic changes and lethality. Eur J Immunol. 1994; 24:2237-42.
47. Fattori E, Cappelletti M, Costa P, Sellitto C, Cantoni L, Carelli M, et al. Defective inflammatory response in interleukin 6-deficient mice. J Exp Med. 1994; 180:1243-50.
48. Poli V, Balena R, Fattori E, Markatos A, Yamamoto M, Tanaka H, et al. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J. 1994; 13:1189-96.
49. Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature. 1994; 368:339-42.
50. Kopf M, Ramsay A, Brombacher F, Baumann H, Freer G, Galanos C, et al. Pleiotropic defects of IL-6-deficient mice including early hematopoiesis, T and B cell function, and acute phase responses. Ann N Y Acad Sci. 1995; 762:308-18.
51. Bellido T, Jilka RL, Boyce BF, Girasole G, Broxmeyer H, Dalrymple SA, et al. Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. J Clin Invest. 1995; 95:2886-95.
52. Dalrymple SA, Lucian LA, Slattery R, McNeil T, Aud DM, Fuchino S, et al. Interleukin-6-deficient mice are highly susceptible to Listeria monocytogenes infection: correlation with inefficient neutrophilia. Infect Immun. 1995; 63:2262-8.
53. Brandt SJ, Bodine DM, Dunbar CE, Nienhuis AW. Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. J Clin Invest. 1990; 86:592-9.
54. Gauldie J, Richards C, Baumann H. IL6 and the acute phase reaction. Res Immunol. 1992; 143:755-9.
55. Wolbink GJ, Brouwer MC, Buysmann S, ten Berge IJ, Hack CE. CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexes. J Immunol. 1996; 157:473-9.
56. Culley FJ, Harris RA, Kaye PM, McAdam KP, Raynes JG. C-reactive protein binds to a novel ligand on Leishmania donovani and increases uptake into human macrophages. J Immunol. 1996; 156:4691-6.
57. Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I, et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res. 1996; 11:88-95.
58. Miyasaka N, Sato K, Hashimoto J, Kohsaka H, Yamamoto K, Goto M, et al. Constitutive production of interleukin 6/B cell stimulatory factor-2 from inflammatory synovium. Clin Immunol Immunopathol. 1989; 52:238-47.
59. van Leeuwen MA, Westra J, Limburg PC, van Riel PL, van Rijswijk MH. Clinical significance of interleukin-6 measurement in early rheumatoid arthritis: relation with laboratory and clinical variables and radiological progression in a three year prospective study. Ann Rheum Dis. 1995; 54:674-7.
60. Hirano T, Matsuda T, Turner M, Miyasaka N, Buchan G, Tang B, et al. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol. 1988; 18:1797-801.
61. Wendling D, Racadot E, Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monodonal antibody. J Rheumatol. 1993; 20:259-62.
62. Tanabe M, Ochi T, Tomita T, Suzuki R, Sakata T, Shimaoka Y, et al. Remarkable elevation of interleukin 6 and interleukin 8 levels in the bone marrow serum of patients with rheumatoid arthritis. J Rheumatol. 1994; 21:830-5.
63. Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaisnes CN, Van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 1988; 31:784-8.
64. Gabay C, Roux-Lombard P, de Moerloose P, Dayer JM, Vischer T, Guerne PA. Absence of correlation between interleukin 6 and C-reactive protein blood levels in systemic lupus erythematosus compared with rheumatoid arthritis. J Rheumatol. 1993; 20:815-21.
65. Wilder RL. Neuroendocrine-immune system interactions and autoimmunity. Annu Rev Immunol. 1995; 13:307-38.
66. Wilder RL. Adrenal and gonadal steroid hormone deficiency in the etiopathogenesis of rheumatoid arthritis. J Rheumatol. 1996; 23:10-2.
67. Crofford LJ, Kalogeras KT, Mastorakos G, Magiakou MA, Wells J, Kanik KS, et al. Circadian relationships between interleukin (IL)-6 and hypothalamic-pituitary-adrenal axis hormones: failure of IL-6 to cause sustained hypercortisolism in patients with early untreated rheumatoid arthritis. J Clin Endocrinol Metab. 1997; 82:1279-83.
68. Masi AT, Chrousos GP. Dilemmas of low dosage glucocorticoid treatment in rheumatoid arthritis: considerations of timing. Ann Rheum Dis. 1997; 56:1-4.
69. Linker-Israeli M. Cytokine abnormalities in human lupus. Clin Immunol Immunopathol. 1992; 63:10-2.
70. Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol. 1991; 147:117-23.
71. Spronk PE, ter Borg EJ, Limburg PC, Kallenberg CG. Plasma concentration of IL-6 in systemic lupus erythematosus; an indicator of disease activity? Clin Exp Immunol. 1992; 90:106-10.
72. Swaak AJ, van Rooyen A, Aarden LA. Interleukin-6 (IL-6) and acute phase proteins in the disease course of patients with systemic lupus erythematosus. Rheumatol Int. 1989; 8:263-8.
73. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med. 1995; 332:305-11.
74. Manolagas SC, Jilka RL, Bellido T, O'Brien CA, Parfitt AM. Interleukin-6 type cytokines and their receptors. In: Bilezikian JP, Raisz LG, Rodan GA, eds. Principles of Bone Biology. San Diego: Academic Pr; 1996:701-13.
75. Girasole G, Jilka RL, Passeri G, Boswell S, Boder G, Williams DC, et al. 17 ß-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest. 1992; 89:883-91.
76. Pottratz ST, Bellido T, Mocharia H, Crabb D, Manolagas SC. 17 ß-estradiol inhibits expression of human interleukin-6 promoter-reporter constructs by a receptor-dependent mechanism. J Clin Invest. 1994; 93:944-50.
77. Ray A, Prefontaine KE, Ray P. Down-modulation of interleukin-6 gene expression by 17 ß-estradiol in the absence of high affinity DNA binding by the estrogen receptor. J Biol Chem. 1994; 269:12940-6.
78. Stein B, Yang MX. Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF- B and C/EBP ß. Mol Cell Biol. 1995; 15:4971-9.
79. Passeri G, Girasole G, Jilka RL, Manolagas SC. Increased interleukin-6 production by murine bone marrow and bone cells after estrogen withdrawal. Endocrinology. 1993; 133:822-8.
80. Jilka RL, Hangoc G, Girasole G, Passeri G, Williams DC, Abrams JS, et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science. 1992; 257:88-91.
81. Girasole G, Passeri G, Jilka RL, Manolagas SC. Interleukin-11: a new cytokine critical for osteoclast development. J Clin Invest. 1994; 93:1516-24.
82. Lin SC, Yamate T, Taguchi Y, Borba VZ, Girasole G, O'Brien CA, et al. Regulation of the gp80 and gp130 subunits of the IL-6 receptor by sex steroids in the murine bone marrow. J Clin Invest. 1997; 100:S160.
83. Girasole G, Pedrazzoni M, Giuliani N, Passeri G, Passeri M. Increased serum soluble interleukin-6 receptor levels are induced by ovariectomy, prevented by estrogen replacement and reversed by alendronate administration [Abstract]. J Bone Miner Res. 1995; 10:S160.
84. Chen JT, Maruo N, Kato T, Hasumi E, Ogata E, Shiraki M, et al. Serum level of soluble interleukin-6 receptor, not interleukin-6, is correlated with bone resorption markers and lumbar bone mineral density after menopause [Abstract]. J Bone Miner Res. 1996; 10:S347.
85. Grey A, Mitnick MA, Shapses S, Ellison A, Gundberg C, Insogna K. Circulating levels of interleukin-6 and tumor necrosis factor- are elevated in primary hyperparathyroidism and correlate with markers of bone resorption-a clinical research center study. J Clin Endocrinol Metab. 1996; 81:3450-4.
86. Rusinko R, Yin JJ, Yee J, Saad T, Mundy GR, Guise TA. Parathyroid hormone (PTH) excess is associated with increased interleukin-6 (IL-6) and soluble IL-6 receptor (sIL-6r) production [Abstract]. J Bone Miner Res. 1995; 10:S500.
87. Roodman GD, Kurihara N, Ohsaki Y, Kukita A, Hosking D, Demulder A, et al. Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone. J Clin Invest. 1992; 89:46-52.
88. Klein B, Wijdenes J, Zhang XG, Jourdan M, Boiron JM, Brochier J, et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood. 1991; 78:1198-204.
89. De Benedetti F, Massa M, Pignatti P, Albani S, Novick D, Martini A. Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest. 1994; 93:2114-9.
90. Devlin RD, Bone HG 3d, Roodman GD. Interleukin-6: a potential mediator of the massive osteolysis in patients with Gorham-Stout disease. J Clin Endocrinol Metab. 1996; 81:1893-7.
91. Lakatos P, Kiss L, Tatrai A, Foldes J, Tarjan G, Stern PH. Serum IL-6 levels and bone mineral content in patients with hyper- and hypothyroidism [Abstract]. J Bone Miner Res. 1994; 9:S139.
92. Salvi M, Girasole G, Pedrazzoni M, Passeri M, Giuliani N, Minelli R, et al. Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease. J Clin Endocrinol Metab. 1996; 81:2976-9.
93. Yamamoto T, Ozono K, Kasayama S, Yoh K, Hiroshima K, Takagi M, et al. Increased IL-6 production by cells isolated from the fibrous bone dysplasia tissues in patients with McCune-Albright syndrome. J Clin Invest. 1996; 98:30-5.
94. Langub MC Jr, Koszewski NJ, Turner HV, Monier-Faugere MC, Geng Z, Malluche HH. Bone resorption and mRNA expression of IL-6 and IL-6 receptor in patients with renal osteodystrophy. Kidney Int. 1996; 50:515-20.[Medline]
95. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med. 1995; 332:1351-62.
96. Reichlin S. Neuroendocrinology. In: Wilson JD, Foster DW, eds. Williams Textbook of Endocrinology. 8th ed. Philadelphia: Saunders; 1997:135-219.
97. Elenkov IJ, Papanicolaou DA, Wilder RL, Chrousos GP. Modulatory effects of glucocorticoids and catecholamines on human interleukin-12 and interleukin-10 production: clinical implications. Proc Assoc Am Physicians. 1996; 108:374-81.
98. Donald RA, Bailey RR, Hart D, Livesey JH, Evans MJ, Mattioli L, et al. The plasma interleukin-6 and stress hormone responses to acute pyelonephritis. J Endocrinol Invest. 1994; 17:263-8.
99. Wortel CH, van Deventer SJ, Aarden LA, Lygidakis NJ, Buller HR, Hoek FJ, et al. Interleukin-6 mediates host defense responses induced by abdominal surgery. Surgery. 1993; 114:564-70.
100. Drenth JP, Van Uum SH, Van Deuren M, Pesman GJ, Van der Ven-Jongekrijg J, Van der Meer JW. Endurance run increases circulating IL-6 and IL-1ra but downregulates ex vivo TNF- and IL-1 ß production. J Appl Physiol. 1995; 79:1497-503.
101. Hager K, Machein U, Krieger S, Platt D, Seefried G, Bauer J. Interleukin-6 and selected plasma proteins in healthy persons of different ages. Neurobiol Aging. 1994; 15:771-2.
102. Ershler WB, Sun WH, Binkley N, Gravenstein S, Volk MJ, Kamoske G, et al. Interleukin-6 and aging: blood levels and mononuclear cell production increase with advancing age and in vitro production is modifiable by dietary restriction. Lymphokine Cytokine Res. 1993; 12:225-30.
103. Cohen HJ, Pieper CF, Harris T, Rao KM, Currie MS. The association of plasma IL-6 levels with functional disability in community-dwelling elderly. J Gerontol A Biol Sci Med Sci. 1997; 52:M201-8.
104. Vgontzas AN, Papanicolaou DA, Bixler EO, Kales A, Tyson K, Chrousos GP. Elevation of cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. J Clin Endocrinol Metab. 1997; 82:1313-6.
105. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997; 336:973-9.
106. Bataille R, Klein B. C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. Arthritis Rheum. 1992; 35:982-4.
107. Perrella O, Carrieri PB, Guarnaccia D, Soscia M. Cerebrospinal fluid cytokines in AIDS dementia complex. J Neurol. 1992; 239:387-8.
108. Merrill JE, Chen IS. HIV-1, macrophages, glial cells, and cytokines in AIDS nervous system disease. FASEB J. 1991; 5:2391-7.
109. Wood JA, Wood PL, Ryan R, Graff-Radford NR, Pilapil C, Robitaille Y, et al. Cytokine indices in Alzheimer's temporal cortex: no changes in mature IL-1 ß or IL-1RA but increases in the associated acute phase proteins IL-6, 2-macroglobulin and C-reactive protein. Brain Res. 1993; 629:245-52.
110. Bauer J, Strauss S, Schreiter-Gasser U, Ganter U, Schlegel P, Witt I, et al. Interleukin-6 and -2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett. 1991; 285:111-4.
111. Papanicolaou DA, Torpy DJ, Tsigos C, Defensor R, Thompson B, Chrousos GP. Blunted responses of plasma ACTH and cortisol to a single injection of interleukin-6 (IL-6) in patients with Cushing syndrome. Potential diagnostic use of the IL-6 [Abstract]. 10th International Congress of Endocrinology, 12-15 June 1996, San Francisco, USA. Bethesda, MD: Endocrine Soc Pr; 1996:901.
112. Yanovski JA, Cutler GB Jr, Chrousos GP, Nieman LK. Corticotropin-releasing hormone stimulation following low-dose dexamethasone administration. A new test to distinguish Cushing's syndrome from pseudo-Cushing's states. JAMA. 1993; 269:2232-8.
113. Gold PW, Licinio J, Wong ML, Chrousos GP. Corticotropin releasing hormone in the pathophysiology of melancholic and atypical depression and in the mechanism of action of antidepressant drugs. Ann N Y Acad Sci. 1995; 771:716-29.
114. Crofford LJ, Pillemer SR, Kalogeras KT, Cash JM, Michelson D, Kling MA, et al. Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum. 1994; 37:1583-92.
115. Demitrack MA, Dale JK, Straus SE, Laue L, Listwak SJ, Kruesi MJ, et al. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metab. 1991; 73:1224-34.
Related articles in Annals:
This article has been cited by other articles:
 |
|
 |
|
  A. Sebba Tocilizumab: The first interleukin-6-receptor inhibitor Am. J. Health Syst. Pharm., August 1, 2008; 65(15): 1413 - 1418. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. M. Nater, L. S. Youngblood, J. F. Jones, E. R. Unger, A. H. Miller, W. C. Reeves, and C. Heim Alterations in Diurnal Salivary Cortisol Rhythm in a Population-Based Sample of Cases With Chronic Fatigue Syndrome Psychosom Med, April 1, 2008; 70(3): 298 - 305. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Lim, K. S. Thomas, W. A. Bardwell, and J. E. Dimsdale Which Measures of Obesity Are Related to Depressive Symptoms and in Whom? Psychosomatics, February 1, 2008; 49(1): 23 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S-S. Lee, S. Singh, L. Magder, and M. Petri Predictors of high sensitivity C-reactive protein levels in patients with systemic lupus erythematosus Lupus, February 1, 2008; 17(2): 114 - 123. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Akalin, O. Alatas, and O. Colak Relation of plasma homocysteine levels to atherosclerotic vascular disease and inflammation markers in type 2 diabetic patients Eur. J. Endocrinol., January 1, 2008; 158(1): 47 - 52. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Reilly, V. Poylin, M. Menconi, A. Onderdonk, S. Bengmark, and P.-O. Hasselgren Probiotics potentiate IL-6 production in IL-1beta-treated Caco-2 cells through a heat shock-dependent mechanism Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2007; 293(3): R1169 - R1179. [Abstract] [Full Text] |
Article
